Zevra Therapeutics, Inc.
ZVRA
$12.29
-$0.39-3.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 136.07M | 122.29M | 106.47M | 84.39M | 62.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 136.07M | 122.29M | 106.47M | 84.39M | 62.02M |
| Cost of Revenue | 6.18M | 17.03M | 16.48M | 16.33M | 17.39M |
| Gross Profit | 129.89M | 105.26M | 89.99M | 68.06M | 44.63M |
| SG&A Expenses | 74.73M | 78.95M | 77.71M | 73.44M | 72.71M |
| Depreciation & Amortization | 1.26M | 2.56M | 3.86M | 5.16M | 6.39M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.00M | 112.33M | 110.70M | 113.35M | 122.43M |
| Operating Income | 39.07M | 9.96M | -4.23M | -28.96M | -60.41M |
| Income Before Tax | 69.29M | 133.40M | 86.68M | 53.64M | 21.40M |
| Income Tax Expenses | 11.02M | 9.18M | 3.45M | 18.32M | 18.75M |
| Earnings from Continuing Operations | 58.26 | 124.22 | 83.23 | 35.33 | 2.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.26M | 124.22M | 83.23M | 35.33M | 2.64M |
| EBIT | 39.07M | 9.96M | -4.23M | -28.96M | -60.41M |
| EBITDA | 40.55M | 12.73M | -179.00K | -23.62M | -53.85M |
| EPS Basic | 0.96 | 2.06 | 1.38 | 0.50 | -0.18 |
| Normalized Basic EPS | 0.31 | 0.03 | -0.04 | -0.42 | -0.84 |
| EPS Diluted | 0.92 | 1.99 | 1.33 | 0.47 | -0.21 |
| Normalized Diluted EPS | 0.30 | 0.03 | -0.04 | -0.41 | -0.84 |
| Average Basic Shares Outstanding | 229.91M | 225.54M | 221.22M | 218.30M | 210.16M |
| Average Diluted Shares Outstanding | 236.22M | 231.21M | 225.07M | 219.85M | 211.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |